
Guru Aithal
Professor of Hepatology, Faculty of Medicine & Health Sciences
Contact
Expertise Summary
Drug-induced liver injury (DILI): Genetic and environmental factors associated with drug-induced liver injury, non-invasive markers to detect and monitor hepatotoxicity.
Metabolic liver diseases: Interaction of dietary and genetic factors in the pathogenesis, non-invasive detection and stratification of metabolic dysfunction and alcohol related steatotic liver diseases, interventions to prevent and resolve steatohepatitis.
Technology for life: Magnetic resonance imaging and spectroscopy to evaluate metabolic physiology, pathobiology and its consequences. Advanced imaging and interventions in the pancreatico-biliary tract.
Teaching Summary
Prof Aithal is an Associate Fellow of the Higher Education Academy (2019). He has been an invited faculty for post-graduate course in Europe, USA, Asia and Africa. He is also Joint Advisory Group for… read more
Research Summary
Leader of gastrointestinal and liver theme of the National Institute for Health and Care Research (NIHR)-funded Biomedical Research Unit/ Centre at the Nottingham University Hospitals NHS Trust and… read more
Open Researcher and Contributor ID (ORCID ID), click here
NIHR Nottingham Biomedical Research Centre, Gastrointestinal and Liver Disorder Theme, click here
Cholangiobotics, click here
TransBioline - Translational Safety Biomarker Pipeline, click here
Scarred Liver Project, click here
Prof Aithal is an Associate Fellow of the Higher Education Academy (2019). He has been an invited faculty for post-graduate course in Europe, USA, Asia and Africa. He is also Joint Advisory Group for on GI Endoscopy (JAG) accredited trainer for advanced endoscopic biliary procedures.
Current Research
Leader of gastrointestinal and liver theme of the National Institute for Health and Care Research (NIHR)-funded Biomedical Research Unit/ Centre at the Nottingham University Hospitals NHS Trust and the University of Nottingham for consecutive through four funding cycles (2008-28). Nurtured interdisciplinary collaborations involving biological, physical, engineering, and pharmacological sciences to deliver translational research in hepatobiliary medicine.
Co-chaired international DILI consortium (2010-13) that has identified several HLA, PTPN22, and ERAP2 variants affecting immune tolerance as crucial predisposing factors for DILI from several medications. Polygenic risk score developed from these studies effectively identifies hepatotoxic potential of a wide range of drugs in primary hepatocyte- and stem cell derived- organoids. These results are being incorporated into pre-clinical and clinical drug development as well as 'personalised prescribing' platforms. Deputy Project Co-ordinator of the European Innovation Medicines Initiative (IMI) programme (2019-25) developing novel safety biomarkers for identification of DILI during drug development and clinical practice.
Evaluated serum Pro-C3 and ADAPT algorithm to stratify chronic liver disease. Established the efficacy of peroxisome proliferator-activated receptors in the treatment of metabolic dysfunction associated steatotic liver disease.